Jonathan R. Pollack
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jonathan R. Pollack has a total of 387 co-authors. Here are the top co-authors by number of shared publications:
- James D. Brooks
Department of Urology, Stanford University School of Medicine, Stanford, CA, USA
9 shared publications - Robert B. West
Department of Pathology, Stanford University School of Medicine, Stanford, USA
9 shared publications - Matt van de Rijn
Department of Pathology, Stanford University, Stanford, California
8 shared publications David E. Ong
7 shared publicationsXue Gong
Department of Pathology, Stanford University School of Medicine, Stanford, USA
7 shared publications- Chunde Li
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden ; Department of Clinical Oncology, Karolinska University Hospital, Stockholm, Sweden
6 shared publications
Latest Publications
- 27 October 2026
- Published by Wiley in The Journal of Pathology
Molecular analysis of matched PIN , prostate cancer, and adjacent normal prostate tissue reveals distinct transcriptional signatures and recurrent genomic alterations
Prostate intraepithelial neoplasia (PIN) is a recognized precursor to prostate cancer (PCa) and shares many histological and molecular features with invasive disease. To clarify the relationship between PIN and PCa, we performed integrated genomic and transcriptomic analyses on epithelial and stromal laser‐capture microdissected samples in matched PIN ( n = 121), PCa ( n = 217), and adjacent normal (AN, n = 115) prostate tissue from formalin‐fixed paraffin‐embedded (FFPE) samples across three datasets. We identified two epithelial and two stromal transcriptomic clusters, termed ‘invasive‐like’ and ‘normal‐like’, which were present across all datasets. Among PIN samples, 46% of epithelial and 38% of stromal samples were classified as invasive‐like. Whole‐genome sequencing analysis revealed recurrent copy number alterations in PIN and PCa lesions, with recurrent copy number alterations more frequently shared between invasive‐like PIN and PCa. This study provides new insight into PIN biology and the relationship between PIN and invasive PCa and highlights a transcriptional signature in PIN samples that may have prognostic implications. © 2026 The Pathological Society of Great Britain and Ireland.
- 27 October 2026
- Published by Wiley in The Journal of Pathology
Molecular analysis of matched PIN , prostate cancer, and adjacent normal prostate tissue reveals distinct transcriptional signatures and recurrent genomic alterations
Prostate intraepithelial neoplasia (PIN) is a recognized precursor to prostate cancer (PCa) and shares many histological and molecular features with invasive disease. To clarify the relationship between PIN and PCa, we performed integrated genomic and transcriptomic analyses on epithelial and stromal laser‐capture microdissected samples in matched PIN ( n = 121), PCa ( n = 217), and adjacent normal (AN, n = 115) prostate tissue from formalin‐fixed paraffin‐embedded (FFPE) samples across three datasets. We identified two epithelial and two stromal transcriptomic clusters, termed ‘invasive‐like’ and ‘normal‐like’, which were present across all datasets. Among PIN samples, 46% of epithelial and 38% of stromal samples were classified as invasive‐like. Whole‐genome sequencing analysis revealed recurrent copy number alterations in PIN and PCa lesions, with recurrent copy number alterations more frequently shared between invasive‐like PIN and PCa. This study provides new insight into PIN biology and the relationship between PIN and invasive PCa and highlights a transcriptional signature in PIN samples that may have prognostic implications. © 2026 The Pathological Society of Great Britain and Ireland.
- Open Access
- 3 April 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (11)
Immune repertoire profiling uncovers pervasive T cell clonal expansions in benign prostatic hyperplasia
We discovered T-cell clonal expansions in benign prostatic hyperplasia, indicative of a specific adaptive immune response and with implications for disease pathogenesis and new treatments.
- 3 April 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (11)
Open AccessImmune repertoire profiling uncovers pervasive T cell clonal expansions in benign prostatic hyperplasia
We discovered T-cell clonal expansions in benign prostatic hyperplasia, indicative of a specific adaptive immune response and with implications for disease pathogenesis and new treatments.
- Open Access
- 23 January 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (2)
Spatial transcriptomics identifies candidate stromal drivers of benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is the nodular proliferation of the prostate transition zone in older men, leading to urinary storage and voiding problems that can be recalcitrant to therapy. Decades ago, John McNeal proposed that BPH originates with the “reawakening” of embryonic inductive activity by adult prostate stroma, which spurs new ductal proliferation and branching morphogenesis. Here, by laser microdissection and transcriptional profiling of the BPH stroma adjacent to hyperplastic branching ducts, we identified secreted factors likely mediating stromal induction of prostate glandular epithelium and coinciding processes. The top stromal factors were insulin-like growth factor 1 ( IGF1 ) and CXC chemokine ligand 13 ( CXCL13 ), which we verified by RNA in situ hybridization to be coexpressed in BPH fibroblasts, along with their cognate receptors ( IGF1R and CXCR5 ) on adjacent epithelium. In contrast, IGF1 but not CXCL13 was expressed in human embryonic prostate stroma. Finally, we demonstrated that IGF1 is necessary for the generation of BPH-1 cell spheroids and patient-derived BPH cell organoids in 3D culture. Our findings partially support historic speculations on the etiology of BPH and provide what we believe to be new molecular targets for rational therapies directed against the underlying processes driving BPH.
- 23 January 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (2)
Open AccessSpatial transcriptomics identifies candidate stromal drivers of benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is the nodular proliferation of the prostate transition zone in older men, leading to urinary storage and voiding problems that can be recalcitrant to therapy. Decades ago, John McNeal proposed that BPH originates with the “reawakening” of embryonic inductive activity by adult prostate stroma, which spurs new ductal proliferation and branching morphogenesis. Here, by laser microdissection and transcriptional profiling of the BPH stroma adjacent to hyperplastic branching ducts, we identified secreted factors likely mediating stromal induction of prostate glandular epithelium and coinciding processes. The top stromal factors were insulin-like growth factor 1 ( IGF1 ) and CXC chemokine ligand 13 ( CXCL13 ), which we verified by RNA in situ hybridization to be coexpressed in BPH fibroblasts, along with their cognate receptors ( IGF1R and CXCR5 ) on adjacent epithelium. In contrast, IGF1 but not CXCL13 was expressed in human embryonic prostate stroma. Finally, we demonstrated that IGF1 is necessary for the generation of BPH-1 cell spheroids and patient-derived BPH cell organoids in 3D culture. Our findings partially support historic speculations on the etiology of BPH and provide what we believe to be new molecular targets for rational therapies directed against the underlying processes driving BPH.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
Supplementary Table S1 from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
Supplementary Table S1 from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
Supplementary Table S2 from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
Supplementary Table S2 from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
Supplementary Table S2 from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
Supplementary Table S2 from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Data from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
Supplementary Table S1 from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
Supplementary Table S1 from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Data from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
Prostate cancer is the most common cancer among men in the United States, and aberrant DNA methylation is known to be an early molecular event in its development. Here, we have used expression profiling to identify novel hypermethylated genes whose expression is induced by treatment of prostate cancer cell lines with the DNA methyltransferase inhibitor 5-Aza-2′-deoxycytidine (5-aza-dC). Of the 271 genes that were induced by 5-aza-dC treatment, 25 also displayed reduced expression in primary prostate tumors compared with normal prostate tissue, and the decreased expression of only one gene, aldehyde dehydrogenase 1 family, member A2 (ALDH1a2), was also associated with shorter recurrence-free survival. ALDH1a2 encodes an enzyme responsible for synthesis of retinoic acid (RA), a compound with prodifferentiation properties. By immunohistochemistry, we observed that ALDH1a2 was expressed in epithelia from normal prostate but not prostate cancer. Using bisulfite sequencing, we determined that the ALDH1a2 promoter region was significantly hypermethylated in primary prostate tumors compared with normal prostate specimens (P = 0.01). Finally, transfection-mediated reexpression of wild-type ALDH1a2 (but not a presumptive catalytically dead mutant) in the prostate cancer cell line DU145 resulted in decreased colony growth (P < 0.0001), comparable with treatment with either 5-aza-dC or RA. Taken together, our findings implicate ALDH1a2 as a candidate tumor suppressor gene in prostate cancer and further support a role of retinoids in the prevention or treatment of prostate cancer.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
Prostate cancer is the most common cancer among men in the United States, and aberrant DNA methylation is known to be an early molecular event in its development. Here, we have used expression profiling to identify novel hypermethylated genes whose expression is induced by treatment of prostate cancer cell lines with the DNA methyltransferase inhibitor 5-Aza-2′-deoxycytidine (5-aza-dC). Of the 271 genes that were induced by 5-aza-dC treatment, 25 also displayed reduced expression in primary prostate tumors compared with normal prostate tissue, and the decreased expression of only one gene, aldehyde dehydrogenase 1 family, member A2 (ALDH1a2), was also associated with shorter recurrence-free survival. ALDH1a2 encodes an enzyme responsible for synthesis of retinoic acid (RA), a compound with prodifferentiation properties. By immunohistochemistry, we observed that ALDH1a2 was expressed in epithelia from normal prostate but not prostate cancer. Using bisulfite sequencing, we determined that the ALDH1a2 promoter region was significantly hypermethylated in primary prostate tumors compared with normal prostate specimens (P = 0.01). Finally, transfection-mediated reexpression of wild-type ALDH1a2 (but not a presumptive catalytically dead mutant) in the prostate cancer cell line DU145 resulted in decreased colony growth (P < 0.0001), comparable with treatment with either 5-aza-dC or RA. Taken together, our findings implicate ALDH1a2 as a candidate tumor suppressor gene in prostate cancer and further support a role of retinoids in the prevention or treatment of prostate cancer.
- Open Access
- 8 July 2022
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 114 (12) , 1728
RE: Lower Exome Sequencing Coverage of Ancestrally African Patients in the Cancer Genome Atlas
In their study, Wickland et al. ( 1) reported finding lower exome sequencing coverage among ancestrally African patients in The Cancer Genome Atlas. For 3 cancer types, the lower sequencing coverage could not be explained by lower sequencing depth. The authors therefore attributed the lower sequencing coverage to a “known European bias in the human reference genome” that affected exome capture kit design. We question that inference. The human reference genome was derived mainly from 8 anonymized volunteers in 1997 from Buffalo, NY, USA ( 2). However, the Buffalo population is not, as the authors stated, “almost all European.” The most recent US Census lists the population as 35% Black or African American ( 3). Moreover, the ancestral composition of the human reference genome has previously been studied ( 4, 5). Notably, approximately 70% of the human reference genome was derived from a single male volunteer (library RPCI-11) ( 2). That individual has approximately 50% genetic ancestry each from sub-Saharan Africa and Europe, consistent with being an African American ( 4, 5). Thus, any European bias of the reference genome would be substantially less than supposed (though might still account for some of the authors’ findings). Twenty years after the completion of the Human Genome Project, the sizable African makeup of the human reference genome remains widely unrecognized. Although African genomes are still underrepresented in biomedical studies and databases ( 6), the Human Genome Project at least partially succeeded in mirroring human population diversity.
- 8 July 2022
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 114 (12) , 1728
Open AccessRE: Lower Exome Sequencing Coverage of Ancestrally African Patients in the Cancer Genome Atlas
In their study, Wickland et al. ( 1) reported finding lower exome sequencing coverage among ancestrally African patients in The Cancer Genome Atlas. For 3 cancer types, the lower sequencing coverage could not be explained by lower sequencing depth. The authors therefore attributed the lower sequencing coverage to a “known European bias in the human reference genome” that affected exome capture kit design. We question that inference. The human reference genome was derived mainly from 8 anonymized volunteers in 1997 from Buffalo, NY, USA ( 2). However, the Buffalo population is not, as the authors stated, “almost all European.” The most recent US Census lists the population as 35% Black or African American ( 3). Moreover, the ancestral composition of the human reference genome has previously been studied ( 4, 5). Notably, approximately 70% of the human reference genome was derived from a single male volunteer (library RPCI-11) ( 2). That individual has approximately 50% genetic ancestry each from sub-Saharan Africa and Europe, consistent with being an African American ( 4, 5). Thus, any European bias of the reference genome would be substantially less than supposed (though might still account for some of the authors’ findings). Twenty years after the completion of the Human Genome Project, the sizable African makeup of the human reference genome remains widely unrecognized. Although African genomes are still underrepresented in biomedical studies and databases ( 6), the Human Genome Project at least partially succeeded in mirroring human population diversity.